EPS for Proteon Therapeutics, Inc. (PRTO) Expected At $-0.43

February 15, 2018 - By Marie Mckinney

 EPS for Proteon Therapeutics, Inc. (PRTO) Expected At $ 0.43
Investors sentiment increased to 1.14 in Q3 2017. Its up 0.60, from 0.54 in 2017Q2. It is positive, as 3 investors sold Proteon Therapeutics, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 7.15 million shares or 0.11% more from 7.14 million shares in 2017Q2 were reported.
Royal Retail Bank Of Canada holds 3,375 shares or 0% of its portfolio. Morgan Stanley stated it has 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Perceptive Ltd Llc invested in 334,116 shares or 0.03% of the stock. 25,000 are owned by Kornitzer Capital Inc Ks. Blackrock has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Mpm Asset Mgmt Limited Liability Corporation reported 0.96% stake. Deer Vii holds 10.12% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 315,101 shares. Moreover, Northern has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 13,993 shares. 6,303 were accumulated by Loring Wolcott Coolidge Fiduciary Llp Ma. Moreover, Art Advsrs Limited Liability Corporation has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Limited Liability Partnership reported 2.02 million shares. Acadian Asset Mgmt Ltd holds 0% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 6,990 shares. Virtu Ltd Liability has 11,716 shares for 0% of their portfolio. Renaissance Technologies Lc holds 0% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 171,900 shares. Moreover, Mariner Wealth Advisors Lc has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO).

Since December 15, 2017, it had 1 buying transaction, and 0 insider sales for $22,560 activity.

Analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report $-0.43 EPS on March, 15.They anticipate $0.01 EPS change or 2.38 % from last quarter’s $-0.42 EPS. After having $-1.08 EPS previously, Proteon Therapeutics, Inc.’s analysts see -60.19 % EPS growth. The stock increased 2.14% or $0.045 during the last trading session, reaching $2.145. About 19,190 shares traded. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has declined 80.63% since February 15, 2017 and is downtrending. It has underperformed by 97.33% the S&P500.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Ratings Coverage

Among 8 analysts covering Proteon Therapeutics (NASDAQ:PRTO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. Proteon Therapeutics had 18 analyst reports since November 11, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, April 14 by Robert W. Baird. Oppenheimer maintained the shares of PRTO in report on Wednesday, August 16 with “Hold” rating. H.C. Wainwright downgraded the shares of PRTO in report on Friday, March 17 to “Neutral” rating. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The stock has “Market Perform” rating by JMP Securities on Wednesday, December 14. The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) earned “Strong Buy” rating by Raymond James on Wednesday, October 26. Maxim Group initiated the shares of PRTO in report on Thursday, November 10 with “Buy” rating. The stock has “Hold” rating by Cowen & Co on Tuesday, August 8. Raymond James initiated the stock with “Outperform” rating in Wednesday, November 11 report. Stifel Nicolaus maintained Proteon Therapeutics, Inc. (NASDAQ:PRTO) on Thursday, June 22 with “Hold” rating.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $37.79 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

More notable recent Proteon Therapeutics, Inc. (NASDAQ:PRTO) news were published by: Bioworld.com which released: “Despite PATENCY-1 failure, Proteon Therapeutics vows to press on with vonapanitase” on December 14, 2016, also Marketwatch.com with their article: “Proteon Therapeutics Inc.” published on June 09, 2016, Seekingalpha.com published: “Have You Ever Heard Of Proteon Therapeutics?” on July 19, 2016. More interesting news about Proteon Therapeutics, Inc. (NASDAQ:PRTO) were released by: Marketwatch.com and their article: “Proteon Therapeutics’ stock plummets after failed trial of kidney disease …” published on December 13, 2016 as well as Quotes.Wsj.com‘s news article titled: “Proteon Therapeutics Inc. PRTO (US: Nasdaq)” with publication date: October 18, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.